LLY
Eli Lilly and Company
LLY has the edge over OMCL overall, supported by stronger fundamentals and stronger modeled upside.
OMCL
Omnicell, Inc.
OMCL offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OMCL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
OMCL's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OMCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $34.95 | — |
| Current | 36x | $34.95 | — |
| Cheap | 52x | $49.71 | +42% |
| Fair | 79x | $75.94 | +117% |
| Expensive | 153x | $147 | +320% |
Historical ranges are pointers, not guarantees.
OMCL has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over OMCL on the outlook, with more favorable revenue expectations.
OMCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect OMCL's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OMCL on earnings, with more consistent year-over-year improvement.
OMCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.92 | +100% |
| Q3 2026 | $0.96 | +123% |
| Q2 2026 | $0.84 | +68% |
| Q1 2026 | $0.44 | -4.3% |
| Q4 2025 | $0.04 | -85% |
| Q3 2025 | $0.43 | +$0.82 |
| Q2 2025 | $0.50 | +$0.96 |
| Q1 2025 | $0.46 | +$0.92 |
| Q4 2024 | $0.27 | +$0.72 |
OMCL's earnings per share have fallen from their peak: $0.96 over the past year, against $1.72 in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OMCL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OMCL on profitability, with a higher operating margin.
OMCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $307.9M | -0.9% |
| Q2 2026 | $312.2M | +7.4% |
| Q1 2026 | $309.9M | +15% |
| Q4 2025 | $314M | +2.3% |
| Q3 2025 | $310.6M | +10% |
| Q2 2025 | $290.6M | +5% |
| Q1 2025 | $269.7M | +9.6% |
| Q4 2024 | $306.9M | +19% |
OMCL's revenue is growing: $308M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.8% | +2.2 points |
| Q2 2026 | 10% | +7.6 points |
| Q1 2026 | 5.4% | +9.8 points |
| Q4 2025 | 0.1% | -3.9 points |
| Q3 2025 | 2.6% | +0.3 points |
| Q2 2025 | 2.8% | +1.6 points |
| Q1 2025 | -4.3% | +4.6 points |
| Q4 2024 | 4% | +13 points |
OMCL's operating margin was 4.8% last quarter, up 2.2 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OMCL on cash flow, with more consistent year-over-year improvement.
OMCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +17% |
| Q2 2026 | $59.4M | +92% |
| Q1 2026 | $42.1M | +185% |
| Q4 2025 | $22.6M | -52% |
| Q3 2025 | $18.5M | +33% |
| Q2 2025 | $31M | -37% |
| Q1 2025 | $14.8M | -64% |
| Q4 2024 | $47.2M | +61% |
OMCL still generates free cash flow, though less than at its 2020 peak: $146M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OMCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OMCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +164K shares |
| 1 year | +1.2% | +566K shares |
| 3 years | +1.9% | +871K shares |
| 5 years | -3.9% | -1.9M shares |
| Available history | +8.2% | +3.5M shares |
OMCL has 46M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $61.9M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OMCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.0x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
OMCL has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OMCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 46.9 | Neutral |
OMCL's weekly RSI is 45 (neutral) and its Stochastic is 47 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OMCL PE vs Healthcare Sector
| Metric | OMCL | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 26x | 41% above |
| PE % | 0 | 29 | 29 pts below |
OMCL has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over OMCL on trend strength, trading above more of its moving averages.
OMCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.7 | 2% below |
| 20 week MA | $36.9 | 5.2% below |
| 50 week MA | $39.6 | 12% below |
| 100 week MA | $36.7 | 4.7% below |
| 200 week MA | $40.9 | 15% below |
OMCL is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OMCL on returns for 2026, with the stronger performance.
OMCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $82.5 | $118.2 | +43% |
| 2021 | $118.2 | $175.7 | +49% |
| 2022 | $175.7 | $48.4 | -72% |
| 2023 | $48.4 | $37.6 | -22% |
| 2024 | $37.6 | $44.1 | +17% |
| 2025 | $44.1 | $46.4 | +5.3% |
| 2026 YTD | $46.4 | $35.0 | -25% |
OMCL has finished higher in four of the last six years. It's down 25% so far in 2026.